Drug Profile
REIC gene therapy - Momotaro-Gene
Alternative Names: Ad5-SGE-REIC/Dkk-3; DKK3 gene therapy - Momotaro-Gene; MTG-201; REIC/Dkk-3 gene therapyLatest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator Momotaro-Gene
- Developer Icahn School of Medicine at Mount Sinai; Kyorin Pharmaceutical; Momotaro-Gene
- Class Antineoplastics; Cancer vaccines; Gene therapies
- Mechanism of Action Apoptosis stimulants; DKK3 expression modulators; Gene transference; Tumour suppressor gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant-mesothelioma
- Phase I/II Prostate cancer
- No development reported Liver cancer
Most Recent Events
- 22 Jul 2022 REIC gene therapy is still in phase II trial for Malignant mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT04013334)
- 22 Jul 2022 No development reported - Phase-II for Mesothelioma in Japan (Intratumoural)
- 16 Jun 2022 Momotaro-Gene completes enrolment in its phase II trial for Malignant mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT04013334)